Studies have shown that TUG1 and MEG3 expression levels are reduced in human glioma tissues, with TUG1 promoting cell apoptosis and suppressing proliferation, migration, and invasion, while GAS5 was identified as a suppressor that enhances glioma therapy efficacy by directly targeting miR-222. This evidence concerns the gene MEG3 and central nervous system cancer.